ArticleBMC infectious diseases2025
Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and antibody responses to inactivated COVID-19 vaccines among elderly patients with COPD: a prospective cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to examine adverse events following first, second, and booster doses of Covid-19 vaccines in Malaysia.
methodsThis was a prospective longitudinal cohort study conducted between September 2021 to September 2022. Recipients who received different Covid-19 vaccines (Comirnaty, Vaxzevria, and CoronaVac) completed a self-report questionnaire of adverse events on days 1, 2, 4, and 7 following their primary (first and second) and booster (third) vaccinations.
resultsA total of 1283 respondents had completed the questionnaire survey. The most frequent adverse events among Comirnaty recipients (n = 271) following the first dose were pain (87.4%), fatigue (56.9%), myalgia (37.2%), and fever (17.5%), which further increased to 92.1%, 72.8%, 51·2%, and 48%, respectively, following the booster. The most frequent adverse events following the first dose of Vaxzevria (n = 90) were pain (84.4%), fever (76.7%), headache (58.9%) and myalgia (53.3%). Adverse events were reduced after the second dose of Vaxzevria but sharply increased after the booster. The most common adverse events among CoronaVac recipients (1st dose) were pain at the injection site (69.1%), fatigue (49.1%) and increased hunger (34.5%). However, adverse events subsequently decreased after the second and booster doses. The average number of adverse events was highest for Vaxzevria after the first dose (n = 6) and booster dose (n = 6) and lowest for CoronaVac after the first (n = 3), second (n = 2) and booster doses (n = 2).
conclusionThe incidence of adverse events following the first dose of the Covid-19 vaccine was highest among Vaxzevria recipients. Adverse events following Comirnaty vaccine increased gradually from primary to booster dose, whereas recipients with CoronaVac showed subsequent lesser adverse events following primary and booster doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.